Ticker
ACTI.ST

Price
1.08
Stock movement down
-0.02 (-2.18%)
Company name
Active Biotech AB
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Biotechnology
Market cap
244.40M
Ent value
217.90M
Price/Sales
-
Price/Book
7.88
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-23.23%
3 year return
-22.78%
5 year return
-16.25%
10 year return
-28.12%
Last updated: 2022-08-25

DIVIDENDS

ACTI.ST does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book7.88
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count227.14M
EPS (TTM)-0.24
FCF per share (TTM)-0.23

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-54.20M
Net income (TTM)-54.40M
EPS (TTM)-0.24
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash37.80M
Net receivables3.60M
Total current assets41.50M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets42.30M
Accounts payable0.00
Short/Current long term debt0.00
Total current liabilities11.10M
Total liabilities11.30M
Shareholder's equity31.00M
Net tangible assets30.80M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-52.87M
Capital expenditures (TTM)200.00K
Free cash flow (TTM)-53.07M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-175.48%
Return on Assets-128.61%
Return on Invested Capital-175.48%
Cash Return on Invested Capital-171.18%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.05
Daily high1.10
Daily low1.05
Daily Volume174K
All-time high321.94
1y analyst estimate2.40
Beta0.75
EPS (TTM)-0.24
Dividend per share-
Ex-div date17 Apr 1998
Next earnings date3 Nov 2022

Downside potential

Loading...
Downside potential data
ACTI.STS&P500
Current price drop from All-time high-99.67%-12.18%
Highest price drop-99.72%-56.47%
Date of highest drop8 Mar 20229 Mar 2009
Avg drop from high-91.27%-11.38%
Avg time to new high6417 days12 days
Max time to new high6416 days1805 days
COMPANY DETAILS
ACTI.ST (Active Biotech AB) company logo
Marketcap
244.40M
Marketcap category
Small-cap
Description
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Employees
9
Investor relations
-
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab...
June 1, 2022
The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical att...
May 19, 2022
Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of mye...
May 18, 2022
Active Biotech's Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 28, 2022 Active Biotech AB...
April 28, 2022
Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod ...
April 26, 2022
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07)Active ...
April 21, 2022
The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Thursday, May 19, 2022. Due to the situation resulting from the Corona virus, the M...
April 20, 2022
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024). Today, t...
March 31, 2022
The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK ...
March 25, 2022
FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular pr...
February 9, 2022
Next page